Notably, EC-specific ablation of MLKL effectively attenuates liver fibrosis in NASH by blocking necroptosis and mitigating the TGFβ/Smad 2/3 signaling axis between endothelial cells and HSCs. The gene discussed is MLKL; the disease is metabolic dysfunction-associated steatohepatitis.